Lantheus - LNTH Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month price targets for Lantheus' stock. Their LNTH share price forecasts range from $91.00 to $120.00. On average, they expect the company's share price to reach $102.80 in the next year. This suggests a possible upside of 71.3% from the stock's current price.
View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts.

Lantheus' stock was trading at $50.96 at the start of the year. Since then, LNTH shares have increased by 17.8% and is now trading at $60.02.
View the best growth stocks for 2023 here.

Lantheus saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 3,450,000 shares, a drop of 5.5% from the December 31st total of 3,650,000 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is presently 3.1 days. Currently, 5.1% of the company's shares are short sold.
View Lantheus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our LNTH earnings forecast.

Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its quarterly earnings data on Thursday, November, 4th. The medical equipment provider reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The medical equipment provider had revenue of $102.10 million for the quarter, compared to analyst estimates of $97.13 million. Lantheus had a net margin of 13.35% and a trailing twelve-month return on equity of 37.77%. The business's revenue for the quarter was up 15.4% compared to the same quarter last year. During the same period last year, the business posted $0.04 EPS.

Lantheus updated its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $0.95-$0.98 for the period, compared to the consensus estimate of $0.86. The company issued revenue guidance of $243.00 million-$247.00 million, compared to the consensus revenue estimate of $238.01 million.

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus' stock is owned by many different retail and institutional investors. Top institutional investors include Reinhart Partners Inc. (0.84%), Emerald Advisers LLC (0.62%), Fisher Asset Management LLC (0.52%), Congress Asset Management Co. MA (0.50%), Emerald Mutual Fund Advisers Trust (0.49%) and Allspring Global Investments Holdings LLC (0.45%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends.

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LNTH stock can currently be purchased for approximately $60.02.

Lantheus (NASDAQ:LNTH) has a market capitalization of $4.13 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71,280,000.00 in net income (profit) each year or $1.49 on an earnings per share basis.

The company employs 612 workers across the globe.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.